590 related articles for article (PubMed ID: 18250251)
1. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
3. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
5. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
6. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
7. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
[TBL] [Abstract][Full Text] [Related]
11. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
O'Malley SS; Robin RW; Levenson AL; GreyWolf I; Chance LE; Hodgkinson CA; Romano D; Robinson J; Meandzija B; Stillner V; Wu R; Goldman D
Alcohol Clin Exp Res; 2008 Jul; 32(7):1271-83. PubMed ID: 18482155
[TBL] [Abstract][Full Text] [Related]
13. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
[TBL] [Abstract][Full Text] [Related]
14. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
Oslin DW; Berrettini W; Kranzler HR; Pettinati H; Gelernter J; Volpicelli JR; O'Brien CP
Neuropsychopharmacology; 2003 Aug; 28(8):1546-52. PubMed ID: 12813472
[TBL] [Abstract][Full Text] [Related]
15. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
16. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman D; Oroszi G; O'Malley S; Anton R
J Stud Alcohol Suppl; 2005 Jul; (15):56-64; discussion 33. PubMed ID: 16223057
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM
J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248
[TBL] [Abstract][Full Text] [Related]
18. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
19. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).
Hernandez-Avila CA; Wand G; Luo X; Gelernter J; Kranzler HR
Am J Med Genet B Neuropsychiatr Genet; 2003 Apr; 118B(1):60-5. PubMed ID: 12627468
[TBL] [Abstract][Full Text] [Related]
20. Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Doggrell SA
Expert Opin Pharmacother; 2006 Oct; 7(15):2169-73. PubMed ID: 17020440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]